Is 1mg of finasteride (dihydrotestosterone inhibitor) taken three times a week, on Monday, Wednesday, and Friday, as effective at lowering dihydrotestosterone (DHT) levels as taking 1mg every day in a male patient of reproductive age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Finasteride 1mg Three Times Weekly vs. Daily Dosing for DHT Suppression

No, 1mg of finasteride three times per week (Monday, Wednesday, Friday) is NOT as effective at lowering DHT levels as 1mg daily, though the difference may be clinically modest given finasteride's prolonged pharmacodynamic effects.

Pharmacokinetic and Pharmacodynamic Rationale

The key to understanding this question lies in finasteride's unique pharmacological properties:

  • A single dose of finasteride suppresses serum DHT levels for up to 4 days, which is considerably longer than would be predicted by its serum elimination half-life of 4.7 to 7.1 hours 1

  • This prolonged DHT suppression occurs because finasteride has extremely high affinity for the 5-alpha-reductase enzyme, creating a persistent pharmacodynamic effect that outlasts its presence in serum 1

  • At therapeutic doses, finasteride produces rapid and pronounced DHT reduction, with doses below 0.5mg/day producing minimal DHT suppression, while doses above 5mg/day offer little additional benefit 1

DHT Suppression Data with Standard Dosing

With daily 1mg dosing in normal male volunteers:

  • Serum DHT is reduced by approximately 70% at steady state 2

  • Prostatic tissue DHT is reduced by 80-90% with daily finasteride administration 2

  • DHT levels return to pretreatment values within 14 days of discontinuing treatment 3

Critical Gap in Evidence

There are no published studies directly comparing 1mg three times weekly versus 1mg daily for DHT suppression. The available evidence only addresses:

  • Daily dosing regimens at various doses 1, 3, 2
  • Single-dose pharmacodynamics showing 4-day DHT suppression 1
  • The dose-response relationship showing minimal effect below 0.5mg/day 1

Clinical Implications and Practical Considerations

Given the pharmacological data:

  • Three times weekly dosing (Monday/Wednesday/Friday) creates gaps of 2-3 days between doses, which falls within the 4-day window of DHT suppression from a single dose 1

  • However, steady-state DHT suppression would likely be less consistent compared to daily dosing, with potential fluctuations in DHT levels between doses

  • The clinical significance of these fluctuations is unknown for androgenetic alopecia treatment in reproductive-age men

Important Caveats

Sexual dysfunction risks remain present regardless of dosing frequency, occurring in approximately 2-4% more patients taking finasteride compared to placebo 4, 5

PSA monitoring considerations: After 1 year of 5-ARI therapy, measured serum PSA values should be doubled to accurately assess prostate cancer risk, though this applies primarily to the 5mg dose used for BPH 5, 6

For reproductive-age men concerned about fertility: The 1mg dose has inconclusive evidence regarding fertility impact, while the 5mg dose is associated with reduced semen volume 4

Recommendation for Clinical Practice

If cost or adherence is a concern, three times weekly dosing may provide partial benefit, but daily 1mg dosing remains the evidence-based standard for consistent DHT suppression. The lack of direct comparative data means three times weekly dosing represents an off-label modification without proven equivalence.

References

Guideline

Finasteride 1mg and Male Fertility

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Dutasteride and Hair Changes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.